Abstract library

12 results for "mitoses".
#129 Grade according to Ki-67 or mitotic count in gastroenteropancreatic neuroendocrine tumors
Introduction: Gastroenteropancreatic neuroendocrine tumors (NETs) are uncommon tumors with a reported incidence of 2.5-5 per 100000 population. The recent classification system of NETs proposed by the European Neuroendocrine Tumor Society (ENETS) uses both Ki-67 labelling index and mitotic index to assign grade (low, intermediate, high). It has been adopted into routine practice but there is limited data on the relationship between these indices and their effect on classification.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#507 Are all Metastatic Grade 3 WHO 2010 Neuroendocrine Carcinoma Poorly Differentiated?
Introduction: The WHO classification 2010 for neuroendocrine tumors (NET) defines poorly differentiated neuroendocrine carcinomas (NEC) as grade 3 (G3) according to mitoses> 20/10 HPF and/or Ki-67>20%.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Fritz-Line Vélayoudom-Céphise
#697 Grading NET: Mitosis and Ki-67 conditio sine qua non?
Introduction: The latest WHO classification for neuroendocrine tumors (NET) defines their grade according to Ki-67 and mitotic index. However, as both parameters are markers for a different part of the cell cycle, their values might not lead to the same grade.
Conference: 10th Annual ENETS Conference (2013)
Category: Pathology, grading, staging
Presenting Author: MD PhD Marie-Louise Van Velthuysen
Keywords: grade, Ki-67, mitosis, NET
#1204 Clinico-Pathologic and Survival Analysis of 211 GastroEnteroPancreatic G3 Neuroendocrine Carcinomas (GEP-NECs)
Introduction: GEP-NECs show Ki67>20% and/or >20 mitoses x10 HPF. Mixed AdenoNeuroendocrine Carcinomas (MANECs) are mixed exocrine-neuroendocrine neoplasms. NECs are associated with poor prognosis but recent findings have suggested that there is a fraction of patients showing a better than expected survival rate.
Conference: 12th Annual ENETS Conference (2015)
Category: Pathology, grading, staging
Presenting Author: MD, PhD Massimo Milione
Keywords: NEC, Ki67, MANEC, PROGNOSIS
#114 Downstaging of a gastroenteropancreatic neuroendocrine tumor after combination therapy of temozolomide, Bevacizumab and long-acting somatostatin analogs
Introduction: Patients with gastroenteropancreatic endocrine (GEP) tumors and progressive disease have been treated with several chemotherapeutic regimens with variable responses and considerable toxicity. Recent studies have shown that GEP tumors may respond to therapy with anti-angiogenic agents, mainly as a result of their increased vascularity.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Stavroula Antoniou
#241 One-year Response to Everolimus in a Case of Advanced Pancreatic NET
Introduction: A stage IV pancreatic NET (30 mitoses/10 PF and Ki-67 index=40%) with liver and peritoneal metastases was diagnosed in a 35-year-old woman in June 2008. Characteristics: ECOG2 and CgA 1701 ng/ml.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Paula Jiménez Fonseca
#668 Analysis of the Undifferentiated Neuroendocrine Carcinomas (grade 3) from the Czech Neuroendocrine Registry
Introduction: GEP NETs WHO classification 2010 describes well-differentiated tumors grade 1 and grade 2 and neuroendocrine carcinomas grade 3 with high mitotic index over 20 mitoses /10 HPF or Ki 67 over 20%. Pulmonary neuroendocrine tumor classification 2004 describes typical and atypical carcinoid tumor and small-cell and large-cell neuroendocrine carcinomas with mitotic index over 10 mitoses/ 10 HPF.
Conference: 10th Annual ENETS Conference (2013)
Category: Pathology, grading, staging
Presenting Author: M.D., MBA Eva Sedlackova
#763 Endoscopic Therapy with Argon Plasma Coagulation for Multiple Type 1 Gastric Carcinoid Tumors
Introduction: Data regarding Type I gastric carcinoids and their evolution in prospective series are scarce, thus treatment and follow-up are not codified.
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr. Rodrigo Castano
#939 Large Cell Neuroendocrine Carcinoma of the Gallbladder: A Case Report and Literature Review
Introduction: Primary large cell neuroendocrine carcinoma (LCNEC) of the gallbladder is rare. The standard treatment for gallbladder NEC with liver metastases has not been established, but combination chemotherapy with etoposide plus cisplatin (EP) is recommended for NEC patients with liver metastasis, regardless of the primary tumor site.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: MD Shoichi Nakazuru
Authors: Nakazuru S, Kimura K, Tada Y, Iwasaki R, ...
#1085 Antiproliferative Effect of Lanreotide in Low Grade Neuroendocrine Neoplasms: Two Case Reports
Introduction: Somatostatin analogs are used for control of symptoms due to hormonal hypersecretion by neuroendocrine neoplasms (NEN). Their antiproliferative effect only recently became evident. Data on pancreatic NEN (pNEN) are limited.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: Michael Vaslamatzis
Keywords: NEN, lanreotide
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.